The Long Run with Luke Timmerman Ep158: David Younger and Randolph Lopez on SynBio & AI for Discovery
May 20, 2024
David Younger and Randolph Lopez, co-founders of A-Alpha Bio, discuss using synthetic biology and AI for drug discovery. They explore yeast as a platform, business representation challenges, and innovative approaches to developing antibodies. The podcast dives into how AI revolutionizes drug discovery and optimization, impacting human health through unique biological understanding.
Chapters
Transcript
Episode notes
1 2 3 4 5 6 7 8
Introduction
00:00 • 2min
Founders' Journey from Academia to A. Alpha Bio
02:18 • 20min
Exploring Yeast as a Platform for Drug Discovery
22:10 • 7min
Exploring Business Representation and Funding Challenges in Biotech Industry
29:02 • 3min
Exploring the Fusion of Synthetic Biology and AI for Data Analysis
32:25 • 3min
Innovative Approaches to Developing Broad-spectrum Antibodies and Therapeutics
34:57 • 15min
Revolutionizing Drug Discovery Through AI and Platform Engineering
50:05 • 8min
Exploring the Impact of Artificial Intelligence on Drug Discovery and Optimization
58:22 • 2min